Furthermore, clinical data concerning the expression profiles of FOXP4 and AR in endometrioid carcinoma support our experimental conclusion that the progression of endometrioid carcinoma can be controlled by stimulating an androgen/AR system and/or suppressing its downstream molecular target, FOXP4. Here, AR is linked to endometrioid adenocarcinoma.